Molecular Diagnostics: The Key in Personalized Cancer Medicine

Front Cover
Jan Trost Jorgensen, Henrik Winther
Pan Stanford Publishing, Apr 30, 2010 - Medical - 351 pages

This unique book provides a thorough overview of developing molecular cancer diagnostic assays, which are the prerequisites for optimal solutions within personalized cancer medicine. The book takes the reader through definitions of the pharmacodiagnostic concept, historical perspectives of the early steps into molecular cancer diagnostics linked to therapy, the basis of different diagnostic molecular techniques, ongoing research, drug-diagnostic co-development, assay validation, clinical trial methodology, regulatory issues around pharmacodiagnostics and future aspects within personalized cancer medicine.

 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

CHAPTER 1 DEVELOPING MOLECULAR DIAGNOSTICS IN CANCER
1
CHAPTER 2 THE ESTROGEN AND PROGESTERONE RECEPTORS SETTING THE SCENE FOR PHARMACODIAGNOSTICS
21
CHAPTER 3 THE DEVELOPMENT OF THE HERCEPTEST FROM BENCH TO BEDSIDE
43
CHAPTER 4 PREDICTIVE BIOMARKERS AND TRANSLATIONAL CANCER MEDICINE
61
CHAPTER 5 PHARMACODIAGNOSTIC TESTING IMMUNOHISTOLOGY
87
CHAPTER 6 IN SITU HYBRIDISATION FOR PHARMACODIAGNOSTIC TESTING
119
CHAPTER 7 MAMMAPRINT TRANSLATING RESEARCH INTO A DIAGNOSTIC TEST
139
CHAPTER 8 DNA BIOMARKERS IN THE DIAGNOSIS AND MANAGEMENT OF CANCER
165
STATISTICAL CONSIDERATIONS
207
CHAPTER 11 CLINICAL VALIDATION OF BIOMARKERS IN CANCER
227
CHAPTER 12 PHARMACOGENOMIC MARKERS FOR CANCER THERAPY
251
CHAPTER 13 SAFETY AND EFFECTIVE BIOMAKERS IN ONCOLOGY A REGULATORY DRUG AND DEVICE PERSPECTIVE
275
CHAPTER 14 PERSONALIZING TREATMENT SELECTION FOR BREAST CANCER
297
CHAPTER 15 PHARMACODIAGNOSTICS AND PERSONALIZED MEDICINE IN CANCER
325
INDEX
345
Copyright

CHAPTER 9 VALIDATING THE ANALYTICAL POWER AND PARAMETERS OF AN IMMUNOHISTOCHEMICAL TEST
185

Other editions - View all

Common terms and phrases

About the author (2010)

Dr Jan Trøst Jørgensen holds an MSc degree in pharmacy and a PhD in clinical pharmacy from the Faculty of Pharmaceutical Sciences, University of Copenhagen. He has worked with drug development in biotech and pharmaceutical companies for more than 25 years, and within the last 10 years his focus has been on drug-diagnostic co-development projects within cancer. Dr Jørgensen is a strong supporter of more individualized pharmacotherapy and has published a number of scientific papers on oncology as well as on stratified and personalized medicine.

Bibliographic information